Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

Rhea-AI Summary

Outlook Therapeutics (NASDAQ: OTLK) announced its participation in a Virtual Investor Lunch Break Event scheduled for June 25, 2025, at 12:00 PM ET. The company's leadership team, including Lawrence Kenyon (CFO and Interim CEO), Jeff Evanson (CCO), and Jedd Comiskey (SVP - Head of Europe), will discuss commercial strategy, upcoming milestones, and current activities. The event will feature a moderated discussion followed by a live Q&A session. Investors can access the live video webcast through the Events page on Outlook Therapeutics' website, with a replay available for 90 days after the event.

News Market Reaction

-0.59%

1 alert

-0.59% News Effect

On the day this news was published, OTLK declined 0.59%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Live webcast on Wednesday, June 25th at 12:00 PM ET

ISELIN, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will participate in a Virtual Investor Lunch Break Event on Wednesday, June 25, 2025 at 12:00 PM ET.

As part of the event, Lawrence Kenyon, Chief Financial Officer and Interim Chief Executive Officer, Jeff Evanson, Chief Commercial Officer and Jedd Comiskey, Senior VP – Head of Europe, will discuss the Company’s commercial strategy, upcoming milestones and current activities. In addition to the moderated discussion, investors and interested parties will have the opportunity to submit questions live during the event. The Company will answer as many questions as possible in the time allowed.

A live video webcast will be available on the Events page under the Investors section of the Company’s website (outlooktherapeutics.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) to enhance the standard of care for bevacizumab for the treatment of retina diseases. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics commenced commercial launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK as a treatment for wet AMD.

In the United States, ONS-5010/LYTENAVA™ (bevacizumab-vikg) is investigational, and a BLA has been resubmitted to the FDA. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.

Investor Inquiries:

Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
OTLK@jtcir.com

FAQ

When is Outlook Therapeutics (OTLK) Virtual Investor Lunch Break Event?

The event is scheduled for Wednesday, June 25, 2025, at 12:00 PM ET.

Who will be speaking at the OTLK Virtual Investor Event?

Lawrence Kenyon (CFO and Interim CEO), Jeff Evanson (CCO), and Jedd Comiskey (SVP - Head of Europe) will be speaking at the event.

What topics will be discussed at the Outlook Therapeutics investor event?

The discussion will cover the company's commercial strategy, upcoming milestones, and current activities.

How can investors access the OTLK Virtual Investor Event?

Investors can access the live video webcast through the Events page under the Investors section of Outlook Therapeutics' website (outlooktherapeutics.com). A replay will be available for 90 days.